Eicosanoids in cirrhosis and portal hypertension
- 1 October 2003
- journal article
- review article
- Published by Elsevier in Prostaglandins & Other Lipid Mediators
- Vol. 72 (1-2) , 3-18
- https://doi.org/10.1016/s1098-8823(03)00080-7
Abstract
No abstract availableKeywords
This publication has 73 references indexed in Scilit:
- Lipo prostaglandin E1 reduces the production of CXC chemokines in endotoxin-induced rat liver injuryHepatology Research, 2001
- Eicosanoids and the liverProstaglandins & Other Lipid Mediators, 2000
- Does portal hypertension contribute to the pathogenesis of gastric ulcer associated with liver cirrhosis?The Esophagus, 2000
- ROCK Inhibitor Y-27632 Attenuates Stellate Cell Contraction and Portal Pressure Increase Induced by Endothelin-1Biochemical and Biophysical Research Communications, 1999
- Hepatosplanchnic haemodynamics and renal blood flow and function in rats with liver failureGut, 1998
- Reduction of bile secretion by prostaglandins in the rat in vivoLife Sciences, 1996
- Altered prostacyclin synthesis by aortae from hepatic portal vein-constricted rats: evidence for effects on protein kinase C and calciumJournal of Hepatology, 1994
- Oral misoprostol or intravenous prostaglandin E2 do not improve renal function in patients with cirrhosis and ascites with hyponatremia or renal failureJournal of Hepatology, 1993
- Interdependence of tumor necrosis factor, prostaglandin E2, and protein synthesis in lipopolysaccharide‐exposed rat Kupffer cellsEuropean Journal of Biochemistry, 1990
- Identification of prostaglandin D2 as the major eicosanoid from liver endothelial and Kupffer cellsBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1988